Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...3738394041424344454647...143144»
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Menetrier's disease exacerbating ulcerative colitis and relieved by gastrectomy. (Pubmed Central) -  Apr 26, 2022   
    UC management comprised dose-optimised infliximab and methotrexate...Nasojejunal feeding and parenteral nutrition failed to significantly improve nutritional status and accordingly the patient proceeded to radical total gastrectomy. Postoperatively, MD-associated symptoms and hypoalbuminemia resolved completely.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. (Pubmed Central) -  Apr 26, 2022   
    Postoperatively, MD-associated symptoms and hypoalbuminemia resolved completely. The results of this study indicate that AXL may signal through HER3 via NRG1 to promote cetuximab resistance and that targeting of NRG1 could have significant clinical implications for HNC therapeutic approaches.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Bilateral Multifocal Epithelial Defects Due to Cetuximab (Erbitux) Therapy (WEWCC) -  Apr 26, 2022 - Abstract #ASCRSASOA2022ASCRS-ASOA_313;    
    Results In this patient, complete epithelialization was achieved in one eye; however, the fellow eye required more intensive treatment with aggressive lubrication, ofloxacin, and prednisolone acetate therapy, and eventual resolution with use of a dehydrated amniotic membrane disc._x000D_ ConclusionCetuximab therapy induced corneal toxicity is exceedingly rare. To our knowledge this is the first report demonstrating multifocal corneal epithelial defects with use of cetuximab.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    INHIBITION OF HGF MATURATION OVERCOMES CETUXIMAB RESISTANCE IN COLORECTAL CANCER (Poster Hall - San Diego Convention Center) -  Apr 25, 2022 - Abstract #DDW2022DDW_1848;    
    Moreover, cetuximab resistance induced by HGF overexpression could be overcome by the downstream MET inhibition (with crizotinib), and we are now testing if the upstream inhibition of HGF proteases (with ZFH7116/VD2173) also overcomes cetuximab resistance. Combined these Results indicate that inhibition of HGF cleavage and maturation may be a novel way to overcome resistance to EGFR-targeted therapies in CRC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Antitumor Efficacy of EGFR-Targeted Recombinant Immunotoxin in Human Head and Neck Squamous Cell Carcinoma. (Pubmed Central) -  Apr 24, 2022   
    Furthermore, hDT806 resulted in a drastic inhibition in RNA polymerase II carboxy-terminal domain phosphorylation critical for transcription and a significant increase in the γH2A.X level, a DNA damage marker. Thus, the direct disruption of EGFR signaling, transcription inhibition, DNA damage, as well as apoptosis induced by hDT806 may contribute to its antitumor efficacy in HNSCC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Review, Journal:  EGFR-Based Targeted Therapy for Colorectal Cancer-Promises and Challenges. (Pubmed Central) -  Apr 24, 2022   
    The EGFR monoclonal immunoglobulins cetuximab/panitumumab can thus be used to treat colorectal cancer. This review examines carriers that contain cetuximab-conjugated therapeutic drugs as well as their efficacy in anticancer activities.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
    Review, Journal:  Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials. (Pubmed Central) -  Apr 24, 2022   
    Various monoclonal antibodies, such as cetuximab and bevacizumab, which target the EGFR and VEGFR, respectively, as well as other signaling pathway inhibitors, such as temsirolimus and rapamycin, are also being studied for the treatment of HNSCC. We have reviewed the primary targets in active clinical studies in this study, with a particular focus on the medications and drug targets used.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    Clinical, Journal, IO biomarker:  An appraisal of emerging second line therapies for metastatic colorectal cancer. (Pubmed Central) -  Apr 21, 2022   
    Others are necessary because of the biological specificity of the tumor: immunotherapy for tumors with microsatellite instability, or the combination encorafenib cetuximab for mutated BRAF-V600E tumors. In many other circumstances, there are several options that require extensive involvement of multidisciplinary boards and the patient in the final therapeutic decision.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Imfinzi (durvalumab) / AstraZeneca
    P1/2 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal:  Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: a phase 1/2 trial. (Pubmed Central) -  Apr 20, 2022   
    In many other circumstances, there are several options that require extensive involvement of multidisciplinary boards and the patient in the final therapeutic decision. Albeit limited by the small sample size, our preliminary observation of anti-tumor activity and tolerability of Durvalumab in addition to Cetuximab and radiation may warrant further investigations.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Review, Journal:  The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy. (Pubmed Central) -  Apr 19, 2022   
    More studies support the maintenance treatment of anti-EGFR mAb, but some researchers raise the problems about high cost and drug resistance. Despite lack of the maintenance evidence of anti-EGFR mAb, especially lack of large-scale phase III prospective clinical trials, with the emergence of new evidence and more accurate screening of treatment-dominant groups, maintenance therapy with anti-EGFR mAb monotherapy or anti-EGFR mAb combined with fluorouracil-based schemes after first-line chemotherapy combined with anti-EGFR mAb therapy might strive for more treatment opportunities, optimize treatment strategies and prolong treatment continuity, and finally, lead to more survival benefit for suitable patients.
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
    Enrollment change, Trial primary completion date, Metastases:  A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer (clinicaltrials.gov) -  Apr 19, 2022   
    P1/2,  N=88, Recruiting, 
    Despite lack of the maintenance evidence of anti-EGFR mAb, especially lack of large-scale phase III prospective clinical trials, with the emergence of new evidence and more accurate screening of treatment-dominant groups, maintenance therapy with anti-EGFR mAb monotherapy or anti-EGFR mAb combined with fluorouracil-based schemes after first-line chemotherapy combined with anti-EGFR mAb therapy might strive for more treatment opportunities, optimize treatment strategies and prolong treatment continuity, and finally, lead to more survival benefit for suitable patients. N=45 --> 88 | Trial primary completion date: Dec 2021 --> Nov 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer (clinicaltrials.gov) -  Apr 19, 2022   
    P1,  N=24, Recruiting, 
    N=45 --> 88 | Trial primary completion date: Dec 2021 --> Nov 2022 Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
  • ||||||||||  CIML NK - Dana / Farber Cancer Institute
    Trial completion date, Trial primary completion date, Combination therapy, Metastases, Immune cell:  CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov) -  Apr 18, 2022   
    P1,  N=12, Recruiting, 
    Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024 Trial completion date: May 2022 --> Jun 2023 | Trial primary completion date: Apr 2022 --> Dec 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  NCI-2018-02990: Cetuximab in Head and Neck Cancer Patients (clinicaltrials.gov) -  Apr 15, 2022   
    P2,  N=15, Active, not recruiting, 
    Trial completion date: May 2022 --> Jun 2023 | Trial primary completion date: Apr 2022 --> Dec 2022 Recruiting --> Active, not recruiting | N=36 --> 15 | Trial completion date: Mar 2023 --> Jul 2022 | Trial primary completion date: Mar 2022 --> Jun 2022
  • ||||||||||  BMS-986315 / BMS, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS
    Trial completion date, Combination therapy, Monotherapy, Metastases:  Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Apr 15, 2022   
    P1/2,  N=308, Recruiting, 
    Recruiting --> Active, not recruiting | N=36 --> 15 | Trial completion date: Mar 2023 --> Jul 2022 | Trial primary completion date: Mar 2022 --> Jun 2022 Trial completion date: Oct 2024 --> Jun 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, Combination therapy:  Intracellular Co-delivery of native antibody and siRNA for combination therapy by using biodegradable silica nanocapsules. (Pubmed Central) -  Apr 14, 2022   
    This strategy was successfully used in the intracellular co-delivery of siRNA/Cetuximab (also named Erbitux™) for combination therapy in epidermal growth factor receptor (EGFR)-overexpressing cancer cells. These BS-NPs showed good biosafety profiles and antitumor efficacy when administered in vivo, suggesting that the strategy holds potential as a novel delivery platform for combination cancer therapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Journal, Real-world evidence:  Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis. (Pubmed Central) -  Apr 13, 2022   
    Thus, the immunoligand ULBP2:HER2-scFv may represent an attractive biological molecule to promote NK cell cytotoxicity against tumors and to boost ADCC. This retrospective study provides real-world evidence underscoring that anti-EGFR re-exposure strategies might benefit patients independently of the reason for prior discontinuation.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal:  Advances in Organ Preservation for Laryngeal Cancer. (Pubmed Central) -  Apr 12, 2022   
    If the patient is hesitant of chemotherapy or has contraindications to cisplatin, concurrent cetuximab may be offered...They are seen twice in year three, and then yearly until years 5-7. At each of these visits, we have a low threshold to present the patient at our multidisciplinary tumor board for consideration of salvage laryngectomy if there are signs of progression.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, EGFR exon 20:  Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations. (Pubmed Central) -  Apr 12, 2022   
    A 58-year-old woman achieved prolonged stable disease lasting 9 months, while a 76-year-old woman and 38-year-old man maintained a partial response with progression-free survivals of 13 months and 32 months, respectively. In conclusion, cetuximab merits further investigation as it appears to be an additional promising therapy for overcoming EGFR exon 20 insertion-related resistance.